Eunjin Kim

Eunjin Kim

Auto-generated profile, based on publicly available information

Eunjin Kim

Dong-A ST Research Institute, Yongin-si, Gyeonggi-do, Republic of Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in Advanced Synthesis & Catalysis
Verified
Journal Article
Closed access
PDF file
EKEunjin Kim
Eunjin Kim
CLChang Yoon Lee
Chang Yoon Lee
SKSung-Gon Kim
Sung-Gon Kim

1 April 2023 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HKHyun Chul Kim
Hyun Chul Kim
SLSangmi Lee
Sangmi Lee
SSSiyoung Sung
Siyoung Sung
EKEunjin Kim
Eunjin Kim
IJIn-Jin Jang
In-Jin Jang
JCJae-Yong Chung
Jae-Yong Chung
Background: Dapagliflozin formate (DAP-FOR, DA-2811), an ester prodrug of dapagliflozin, was developed to improve the stability and pharmaceutical manufacturing process of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor. Purpose: This study aimed to evaluate the pharmacokinetics (PKs) and safety of dapagliflozin for DAP-FOR compared to those for dapagliflozin propanediol monohydrate (DAP-PDH, Forxiga) in healthy subjects. Methods: This was an open-label, randomized, single-dose, two-period, two-sequence crossover study. The subjects received a single dose of DAP-FOR or DAP-PDH 10 mg in each period, with a 7-day washout. Serial blood samples for PK analysis were collected up to 48 hours after a single administration to determine plasma concentrations of DAP-FOR and dapagliflozin. PK parameters were calculated using a non-compartmental method and compared between the two drugs. Results: In total, 28 subjects completed the study. DAP-FOR plasma concentrations were not detected in all of the blood sampling time points except for one time point in one subject, and the corresponding DAP-FOR plasma concentration in the subject was close to the lower limit of quantification. The mean plasma concentration–time profiles of dapagliflozin were comparable between the two drugs. The geometric mean ratios and its 90% confidence intervals of the maximum plasma concentration and area under the plasma concentration–time curve of dapagliflozin for DAP-FOR to DAP-PDH were within the conventional bioequivalence range of 0.80– 1.25. Both drugs were well-tolerated, with a similar incidence of adverse drug reactions. Conclusion: The rapid conversion of DAP-FOR into dapagliflozin led to the extremely low exposure of DAP-FOR and comparable PK profiles of dapagliflozin between DAP-FOR and DAP-PDH. The safety profiles were also similar between the two drugs. These results suggest that DAP-FOR can be used as an alternative to DAP-PDH.